Table 2.
Adjusteda HR (95% CI) of log-transformed hs-troponin (per 1 SD increase) with all-cause and cardiovascular mortality, overall and by subgroups of interest
| n/N | Roche hs-troponin T | Abbott hs-troponin I | Siemens hs-troponin I | Ortho hs-troponin I | |
|---|---|---|---|---|---|
| hazard ratio (95% CI) | hazard ratio (95% CI) | hazard ratio (95% CI) | hazard ratio (95% CI) | ||
| All-cause mortality | |||||
| Overall | 2188/9810 | 1.31 (1.21–1.42) | 1.20 (1.13–1.28) | 1.10 (1.02–1.18) | 1.23 (1.14–1.33) |
| Age group | |||||
| 18–39 years | 113/3902 | 1.02 (0.83–1.24) | 0.97 (0.78–1.22) | 0.92 (0.76–1.11) | 1.02 (0.79–1.31) |
| 40–59 years | 392/3022 | 1.30 (1.09–1.54) | 1.10 (0.96–1.24) | 0.97 (0.82–1.15) | 1.15 (0.98–1.34) |
| 60 years or older | 1683/2886 | 1.33 (1.21–1.45) | 1.30 (1.23–1.37) | 1.30 (1.19–1.42) | 1.36 (1.19–1.55) |
| P-interaction | <0.001 | 0.01 | <0.001 | 0.01 | |
| Sex | |||||
| Male | 1163/4579 | 1.18 (1.06–1.30) | 1.15 (1.05–1.26) | 1.03 (0.90–1.18) | 1.13 (0.99–1.29) |
| Female | 1025/5231 | 1.49 (1.32–1.67) | 1.26 (1.16–1.36) | 1.14 (1.03–1.26) | 1.31 (1.15–1.49) |
| P-interaction | 0.01 | 0.13 | 0.22 | 0.18 | |
| Race/ethnic group | |||||
| Non-Hispanic White | 1267/4966 | 1.30 (1.19–1.42) | 1.22 (1.12–1.33) | 1.12 (1.00–1.25) | 1.26 (1.13–1.41) |
| Non-Hispanic Black | 385/1730 | 1.39 (1.17–1.64) | 1.14 (1.03–1.27) | 1.11 (0.89–1.40) | 1.11 (0.95–1.30) |
| Mexican American | 413/2305 | 1.23 (0.97–1.57) | 1.22 (1.03–1.44) | 1.07 (0.78–1.48) | 1.33 (1.09–1.63) |
| Other | 123/809 | 1.39 (1.12–1.73) | 1.15 (0.89–1.49) | 0.98 (0.80–1.20) | 1.13 (0.78–1.64) |
| P-interaction | 0.004 | 0.009 | 0.209 | 0.004 | |
| CVD mortality | |||||
| Overall | 488/9810 | 1.49 (1.28–1.75) | 1.44 (1.26–1.66) | 1.45 (1.06–1.97) | 1.65 (1.23–2.22) |
| Age group | |||||
| 18–39 year | 16/3902 | 0.91 (0.38–2.19) | 0.92 (0.51–1.64) | 0.88 (0.33–2.35) | 0.70 (0.37–1.34) |
| 40–59 year | 75/3022 | 1.31 (0.95–1.80) | 1.16 (0.82–1.64) | 0.97 (0.60–1.58) | 1.32 (0.87–2.02) |
| 60 year or older | 397/2886 | 1.57 (1.28–1.91) | 1.63 (1.40–1.89) | 1.89 (1.50–2.39) | 2.04 (1.54–2.72) |
| P-interaction | 0.69 | 0.42 | 0.05 | 0.03 | |
| Sex | |||||
| Male | 265/4579 | 1.33 (1.09–1.62) | 1.38 (1.17–1.62) | 1.34 (0.96–1.88) | 1.64 (1.17–2.30) |
| Female | 223/5231 | 1.68 (1.33–2.11) | 1.50 (1.24–1.83) | 1.49 (1.01–2.19) | 1.62 (1.12–2.35) |
| P-interaction | 0.006 | 0.149 | 0.319 | 0.56 | |
| Race/ethnic group | |||||
| Non-Hispanic White | 296/4966 | 1.54 (1.28–1.85) | 1.52 (1.29–1.78) | 1.65 (1.18–2.32) | 1.89 (1.34–2.67) |
| Non-Hispanic Black | 94/1730 | 1.41 (0.97–2.05) | 1.16 (0.90–1.48) | 1.07 (0.59–1.92) | 1.38 (0.97–1.96) |
| Mexican American | 75/2305 | 1.40 (0.88–2.23) | 1.33 (0.76–2.32) | 1.28 (0.97–1.67) | 1.33 (0.80–2.22) |
| Other | 23/809 | 1.03 (0.60–1.77) | 1.05 (0.71–1.53) | 0.81 (0.36–1.82) | 0.74 (0.40–1.38) |
| P-interaction | 0.011 | 0.035 | 0.030 | 0.001 | |
CVD, cardiovascular disease; SD, standard deviation; eGFR, estimated glomerular filtration ratio.
hs-troponin modeled as a continuous (per 1 SD increase on the log scale) exposure and adjusted for age, sex, race/ethnicity, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, cigarette smoking status, diabetes mellitus, family history of CVD, body mass index, use of blood pressure medications, use of cholesterol-lowering medications, and eGFR.